Compare

GRAIL/$GRAL

1D1W1M3M6MYTD1Y5YMAX

About GRAIL

GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
Ticker
$GRAL
Sector
Health
Primary listing
NASDAQ
Employees
910
Website
grail.com

GRAIL Metrics

BasicAdvanced
$5.2B
-
-$9.27
2.87
-

What the Analysts think about GRAIL

Analyst ratings (Buy, Hold, Sell) for GRAIL stock.
Analyst projections of the future price of GRAIL stock.

Bulls say / Bears say

In the NHS-Galleri trial, later screening rounds showed fewer stage IV diagnoses, and emergency cancer presentations were lower in the test group. These encouraging signals suggest Galleri may help shift some diagnoses to an earlier point, although the trial’s main endpoint was not met. (PubMed Central)
The FDA advisory panel voted in favour of Galleri, bringing a potential approval decision closer. Approval could open a path to Medicare coverage from 2028, which would materially broaden access if coverage is secured. (Reuters)
Galleri test volumes grew 24% year over year in the third quarter and 36% over the first nine months of 2026. That growth suggests demand is building even before FDA approval or broad insurance coverage. (GRAIL)
The large NHS-Galleri trial did not meet its main goal: the combined rate of stage III and IV cancers was not significantly lower with screening. Whether Galleri reduces cancer deaths remains unproven. (PubMed Central)
Galleri detected only about 31% of all cancers diagnosed within a year of a test in the NHS trial, so a negative result can miss many cancers. Around half of positive results led to a cancer diagnosis, leaving others to face follow-up tests without a cancer finding. (BJC Reports)
Commercial growth is not yet translating into stronger financial performance: third-quarter revenue rose just 4%, while the adjusted EBITDA loss widened to $92.6 million. This leaves GRAIL dependent on continued funding while it builds its market. (GRAIL)
Data summarised monthly by Lightyear AI. Last updated on 14 Nov 2026.

GRAIL Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

GRAIL Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.